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Legal Highs and Lows 
As new psychoactive substances (NPS) flood the market and “designer drug” sales are 
on the rise, we are faced with significant – and growing – social and analytical challenges. 
Here, I offer an overview of a quietly unraveling crisis.  
By Amira Guirguis, pharmacist and visiting lecturer, Department of Pharmacy, University of 
Hertfordshire, Hatfield, UK. 
While serving as a hospital pharmacist, I frequently encountered patients with marijuana 
hidden in their belongings; often, they declared them as personal “herbal medicines”. At the 
same time, the use of “designer drugs” was increasing and it was not uncommon to encounter 
numerous admissions with unknown sources of toxicities. The lack of available clinical 
guidelines for treating designer drug-related toxicity made it challenging and led to the 
provision of supportive adjunct treatment as well as treating the symptoms themselves. 
Furthermore, symptom control was based on local formularies used by different hospitals rather 
than national guidelines (1). These challenges inspired me to undertake a PhD research project 
to study and investigate the new flood of “designer drugs”. This has led me into contributing 
to two EU-funded projects that focus on the problem of NPS: EU-MADNESS 
(www.eumadness.eu) and Enhancing Police Skills regarding NPS (http://www.npsproject.eu/). 
No control = crisis 
NPS are synthetic drugs made for recreational use that are not subject to international control 
(2). To circumvent the law, NPS manufacturers slightly modify the structure of established 
drugs of abuse, while retaining their pharmacological effects (1) (Table 1). NPS are sold and 
marketed with labels that do not reflect the actual content of the product. Indeed, they are often 
branded with confusing and frankly ridiculous names such as “Dr. Booga Shooga” or “meow 
meow”, labeled as “research chemicals”, “legal highs”, “food supplements”, “bath salts”, 
“plant food”, or “herbal highs”, with complex acronyms, such as AH-7921 or 251-NBOMe (or 
Nbomb). The ban of one drug has been shown to be associated with rapid replacement by an 
alternative “legal and uncontrolled” drug and has actually resulted in the proliferation of the 
NPS market, with increased diversity of products, users, distributors and risks. 
Table 1: Structural similarity between emerging NPS and traditional drugs of abuse 
NPS Traditional drugs of abuse 
 
Cathinone 
 
 
 
 
Amphetamine 
 
Methylone 
 
 
Ecstasy 
 
In contrast to the limited number of traditional drugs of abuse, such as cocaine, heroin and 
ecstasy, the number of NPS is increasing dramatically and there is no sign of the market 
slowing down. Internet sales and the ease with which new online markets are created 
contributes to the crisis. Currently, the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is monitoring more than 500 NPS. The EMCDDA has also reported 
that more than two drugs appeared on the market each week in 2014. And the reported number 
of NPS seizures in Europe has also increased seven-fold between 2008 and 2013 (2). 
The EMCDDA categorises NPS as piperazines, benzodiazepines, arylamines, tryptamines, 
opioids, phenethylamines, synthetic cathinones, synthetic cannabinoids and others (see Figure 
1). Synthetic cathinones and synthetic cannabinoids are the most popular classes of NPS in 
Europe since 2009. According to the EMCDDA report (March 2015), the NPS market has 
expanded to include “legal highs” (marketed with bright packaging and attractive brands, and 
sold in headshops and over the Internet); “research chemicals” sold over the Internet “for 
scientific research” (with labels imitating safety data sheets). Such NPS are more attractive to 
“psychonauts”, who like to try “new stuff” rather than get addicted to one drug. NPS also 
include food supplements sold in fitness shops and over the Internet and “designer drugs” sold 
as traditional drugs of abuse by drug dealers in the illicit drug market. The products often 
contain one or more NPS but can also contain diverted prescription medicines sold by drug 
dealers in the illicit drug market.  
The term “legal highs” is undesirable and misleading. It gives the impression that these 
products are legal and safe when they may contain controlled substances (drugs or their 
precursors) and harmful contaminants. It also gives the impression that these NPS induce 
“highs”, when in fact some of them are depressants or have overlapping pharmacological 
effects. 
 Figure 1. New psychoactive substances in Europe. An update from the EU Early Warning 
System (March 2015, Reproduced with permission from the EMCDDA) 
  
In addition, there is evidence that NPS are used in combination with traditional drugs of abuse 
and/or alcohol. In other cases, NPS replace the use of traditional drugs of abuse; for example, 
heroin injectors are now moving onto injecting mephedrone because it is cheaper but has 
similar psychoactive effects.  
A recipe for social disaster 
 
NPS emerged after the drug cookery books written by Alexander (Sasha) and Anna Shulgin 
became available in the late 1990s (3-4). In 2009, NPS appeared in huge numbers and became 
internationally popular for different reasons primarily because they are legal, cheap, 
“undetectable”, and provide desired effects such as euphoria, increased sociability, elevated 
mood, hallucinations, increased libido and so on. Users of NPS include people of all ages and 
persuasions: students, lesbians, gay bisexual and transgender (LGBT), people interested in 
‘chemsex’, heroin users, clubbers, gym-users, the homeless population, prisoners, and users of 
substance misuse and needle-and-syringe-exchange schemes. Knowledge of the patterns of 
NPS abuse mainly depends on anecdotal self-reported user surveys and user experiences shared 
in drug fora, for example Erowid and Bluelight. NPS can be snorted, smoked, injected, ingested 
(sometimes via bombing, in which the drug is placed in paper, rolled into a ball and ingested) 
or dissolved in alcohol. 
 
Toxic ignorance  
Information regarding NPS intoxication is very limited due to the lack of data from hospital 
emergency departments, walk-in centres, and so on. Nevertheless, the EMCDDA issued 16 
public health alerts in 2014 for NPS associated with serious harm, such as hospitalisation and 
death. Published case studies highlight some of the toxic effects of NPS and include UK cases 
of sympathomimetic toxicity from the intake of mephedrone (3), attempted murder resulting 
from the combined intake of 3-methoxyphencyclidine (3-MeO-PCP) and 
methylenedioxypyrovalerone (MDPV) (4), lethal serotonin syndrome after the combined 
ingestion of methylone and butylone (5), and death from taking the diet pill, 2,4-dinitrophenol 
(or DNP) (6). NPS effects on different body systems such as the sympathetic nervous system, 
cardiovascular, or neurological systems is dependent on the amount taken, and the number and 
type of drugs co-ingested/injected, all of which have different clinical implications.  
The 2011/12 Crime Survey for England and Wales (CSEW) has reported that ketamine users 
generally have high rates of simultaneous poly-use (7). Ketamine has also been linked to 
significant sexual health risks (8) and the prevalence of premature death among the drug-
injecting population (9). For mephedrone alone, a synthetic cathinone, presentations for 
treatment rose in England from 839 in 2010/11 to 900 in 2011/12 amongst clients aged 18 years 
and over (10). And the number of mephedrone-related TOXBASE accesses (a primary clinical 
toxicology database) was 7061 in 2013/14, 8432 in 2011/12 and 6169 in 2011/12 (11–13). 
The explosive emergence of NPS, the anonymity of Internet sales and the emergence of 
“cryptomarkets” are posing great challenges for policy-makers and law-enforcements agencies. 
NPS are not currently under any international control, although many countries have 
established permanent control measures for some NPS or issued temporary bans. For example, 
in April 2010 the UK classified cathinones as controlled drugs under Schedule II of the Misuse 
of Drugs Act 1971 through a generic definition i.e., banning all emerging NPS that are made 
by slightly modifying the generic chemical structure of cathinones. Conversely, selected 
cathinones were placed under temporary orders in the USA such as the cathinone 4-MEC (4-
methylethcathinone), which was only classified as a schedule I controlled drug in 2014. The 
downside of the generic definition ban of classes of NPS is that some new analogs have fallen 
outside of the generic definition and became legal analogs to controlled drugs. Naphyrone, 
which emerged to the market following the ban in July 2010, is an example. Therefore, the 
generic definition was modified to include it. This was followed by the emergence of bk-2C-
B, which remains a legal cathinone in the UK. 
Root of the problem 
India and China produce large quantities of legal high products. And the fact that they can also 
be manufactured from legal precursors of known tested pharmaceuticals facilitates large-scale 
production. The drugs are exported legally to Europe, where they are cut and distributed across 
the vast Internet market. The drugs are typically cut with a variety of controlled or uncontrolled 
active ingredients, prescription medicines and inert substances. Figure 2 shows example 
chemical structures for NPS categorised by EMCDDA. 
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Figure 2: Example chemical structures for NPS categories (EMCDDA, 2015) 
Danger of the unknown 
Limited information is available on the pharmacology and toxicology of NPS (14, 15). NPS 
may exhibit stimulant, depressant, empathogenic, aphordiasic, dissociative, hallucinogenic, 
entactogenic and psychotropic effects. Most NPS exhibit psychoactive and sympathomimetic 
features (16), with the possibility of NPS classes overlapping and sharing one or more 
psychoactive effects (17) because most street drugs are sold as racemic mixtures.  
Potencies, toxicities, pharmacokinetics and pharmacodynamics depend on whether the drug 
exists as a single enantiomer or a mixture of both enantiomers. If both enantiomers exist, their 
dynamics may be altered due to potential synergistic or competitive actions. Additionally, the 
enantiomeric fraction may change over time because of preferential metabolism of one over 
the other (18). Let’s take just one example: cathinone analogues exhibit various 
pharmacological effects, which include stimulant, empathogenic and anti-depressant effects 
(19, 20).  Coppola et al (2012) and Cozzi et al (1999) showed that cathinones might exert their 
stimulant effect by inhibiting the enzymes tyrosine hydroxylase and tryptophan hydroxylase, 
which are responsible for the synthesis of dopamine (DA) and serotonin (5-HT) (21, 22). 
Cathinones also inhibit the re-uptake of the neurotransmitters DA, 5-HT and norepinephrine 
(NE) by the monoamine transporters, which then reduces clearance of neurotransmitters from 
the synaptic cleft. Additionally, they induce the release of newly synthesised monoamines from 
the cytoplasm as well as stored monoamines from the synaptic vesicle stores. These 
pharmacological effects result in reduced concentrations of monoamines in the frontal cortex, 
hippocampus and neostriatum. Reduced catecholamine concentrations have been shown to 
extend for up to 30 days leading to the destruction of monoaminergic neurons (23, 24). 
Specialised, portable, in-field analysis 
The global proliferation of NPS is posing international public health risks and a pronounced 
burden for first responders. In-field detection of NPS is crucial for law enforcement agents, 
where the identification of unknown compounds is important for making decisions (for 
example, making an arrest). Fortunately over the past decade, handheld techniques have 
become available, which have the advantage of bringing the lab to the sample (5). A recent 
development includes the use of surface-enhanced Raman spectroscopy (SERS – for more, see 
page XX) for the detection of mephedrone, with a limit of detection of 1.6 µg mL-1 (25). 
Presumptive tests have also been used for the identification of cathinones (26), but because 
such tests depend on the presence of a functional group, they can lead to false positives. Other 
rapid tests include immunoassays, which are commonly used for in-field detection of drugs of 
abuse (27) and NPS in biological matrices, such as urine (28). These kits are limited by the fact 
that they must be developed for known specific drugs and cannot be used for unknown, new 
NPS (28). In addition, their excellent selectivity prevents the identification of NPS analogues 
due to low cross-reactivity (29), which may yield false negative results (27, 30). An on-the-
spot screening instrument was recently developed and involved the use of disposable electro-
analytical sensors for identifying three cathinones (31). Yet, the latter studies investigated NPS 
samples in solution rather than in solid state.  
Handheld techniques employing Fourier transform infrared or Raman spectroscopy are the 
main analytical techniques employed by forensic scientists for the screening and identification 
of NPS. According to the United Nations Office on Drugs and Crimes (UNODC), gas 
chromatography-mass spectrometry (GC-MS) is considered the main wet chemical technique 
used in forensic labs for the analysis of seized NPS or NPS and their metabolites in body fluids 
such as urine. So, should a sample test positive in the field, it may be transported to a forensic 
lab and tested using GC-MS. High performance liquid chromatography (HPLC) is also used 
for quantification of selected NPS.  
We need you! 
Certainly, analytical chemistry plays an important role in screening, identifying and 
quantifying NPS products; rapid identification and quantification ensures swift 
arrests/confiscations, aids in treatment decisions in healthcare settings, and assists with 
preventing the widespread distribution of harmful substances. However, we still need more 
analytical developments to overcome the challenges of “designer drugs”. For example, we lack 
reference standards for many drug samples because of the pace at which new drugs emerge on 
the market and the cost of synthesizing them. To evade detection and circumvent the law, 
clandestine chemists have been able to produce heterogeneous NPS products (32). And as 
mentioned earlier, NPS are often intentionally branded and mislabeled, which adds complexity 
and makes the identification of NPS and the discrimination between NPS and excipients 
difficult. Other challenges faced include the presence of contaminants, coloured powders and 
unknown constituents and limitations of conventional in-field immunoassay kits. For example, 
signals resulting from excipients intentionally mask and hinder NPS identification. Finally, 
NPS products may contain controlled drugs, which requires analytical labs to hold specific 
expensive licenses, which hinders “designer drug” research. 
Traditional harm reduction techniques are difficult to apply to NPS because they are 
continuously emerging with fantasy names, different mixtures, novel analogues, precursors and 
diverse chemical structures. It is crucial to develop evidence-based harm reduction services by 
raising awareness and educating the public. Exchange information between different countries 
through the projects like the European Early Warning System is also indispensable. Despite 
being debatable, new policy is essential when it comes to tackling the NPS problem; the coming 
into force in April of the UK’s Psychoactive Substances Act 2016 is aimed at effecting a 
“Blanket ban” on NPS without hindering NPS-related research, but it may simply lead to 
increased clandestine activities.  
So far, clandestine chemists have always been one-step ahead. In addition to developing more 
efficient on-site testing to avoid false positives and false negatives, analytical chemists need to 
collaborate with forensic and law enforcement agencies and service providers to predict future 
generations of NPS. We need methods that unambiguously identify these drugs before they can 
cause harm. 
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